Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andy Chen
WLF

Andy Chen

Wolfe Research
Wall Street Analyst
★★★☆☆
#1393
on 13Foresight · ranked by our own returns
59%
Success Rate
+50.5%
Average Return
23 of 39 calls profitable · +34.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 59% of Andy Chen's ratings turned a profit when each position was held for 2 year — averaging +50.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

19 Buy 10 Hold 1 Sell
Andy's Stock Coverage 30 ratings · 2026-11-11
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
ROIV
Roivant Sciences
 Oct 12, 2026 HOLD Strong Buy
+10.7% avg upside
19 analysts
 — +19.1% ·
INSM
Insmed
 Oct 12, 2026 HOLD Strong Buy
+51.3% avg upside
37 analysts
 — +21.2% ·
KYMR
Kymera Therapeutics
 Sep 10, 2026 BUY Strong Buy
-9.6% avg upside
39 analysts
$180.00
42.09% Upside
 +16.8% ·
MDGL
Madrigal Pharmaceuticals
 Aug 04, 2026 BUY Strong Buy
+20.2% avg upside
34 analysts
$605.00
40.65% Upside
 -14.8% ·
VRTX
Vertex Pharmaceuticals
 Aug 03, 2026 BUY Strong Buy
-20.5% avg upside
62 analysts
$557.00
0.24% Downside
 +16.5% ·
SYRE
Spyre Therapeutics
 Jul 28, 2026 HOLD Strong Buy
+0.9% avg upside
25 analysts
 — +3.9% ·
NTLA
Intellia Therapeutics
 Jul 15, 2026 SELL Buy
+187.2% avg upside
39 analysts
$9.00
27.74% Downside
 +10.7% ·
IONS
Ionis Pharmaceuticals
 Jul 15, 2026 HOLD Strong Buy
+74.1% avg upside
44 analysts
 — -43.4% ·
SRPT
Sarepta Therapeutics
 Jul 08, 2026 BUY Buy
+223.8% avg upside
50 analysts
$27.00
45.10% Upside
 -11.8% ·
CLDX
Celldex
 Jun 14, 2026 BUY Strong Buy
+42.9% avg upside
28 analysts
$44.00
46.17% Upside
 -4.0% ·
ABVX
Abivax SA Sponsored ADR
 Jun 03, 2026 BUY Strong Buy
+54.7% avg upside
16 analysts
$136.00
57.10% Upside
 -0.2% ·
VERA
Vera Therapeutics
 Jun 02, 2026 BUY Strong Buy
+114.1% avg upside
19 analysts
$88.00
184.00% Upside
 -4.7% ·
AVTX
Avalo Therapeutics
 Apr 08, 2026 BUY Strong Buy
+561.5% avg upside
20 analysts
$48.00
569.55% Upside
 -51.9% ·
PALI
Palisade Bio
 Apr 08, 2026 BUY Strong Buy
+2087.9% avg upside
16 analysts
$7.00
503.48% Upside
 -39.6% ·
DNTH
Dianthus Therapeutics
 Apr 08, 2026 BUY Strong Buy
+23.4% avg upside
32 analysts
$98.00
18.96% Upside
 +1.4% ·
PHVS
Pharvaris
 Apr 08, 2026 BUY Strong Buy
+67.0% avg upside
15 analysts
$42.00
25.23% Upside
 +26.2% ·
IMVT
Immunovant
 Apr 06, 2026 BUY Strong Buy
+38.4% avg upside
25 analysts
$47.00
61.06% Upside
 +38.0% ·
MLTX
MoonLake Immunotherapeutics
 Mar 23, 2026 BUY Strong Buy
+158.9% avg upside
20 analysts
$24.00
103.66% Upside
 -31.6% ·
ARGX
Argenx Se
 Nov 24, 2025 HOLD Strong Buy
-8.2% avg upside
48 analysts
 — +7.1% ·
IVA
Inventiva
 Nov 05, 2025 BUY Strong Buy
+350.3% avg upside
17 analysts
$13.00
256.17% Upside
 -5.4% ·
ALNY
Alnylam Pharma
 Aug 04, 2025 HOLD Strong Buy
+76.3% avg upside
53 analysts
 — -63.9% ·
BBIO
BridgeBio Pharma
 Jun 16, 2025 BUY Strong Buy
+26.0% avg upside
36 analysts
$49.00
34.64% Downside
 +91.2% ·
ANAB
AnaptysBio
 May 21, 2025 BUY Strong Buy
+48.7% avg upside
26 analysts
$25.00
48.30% Downside
 +245.8% ·
INCY
Incyte
 Mar 17, 2025 BUY Buy
-5.9% avg upside
49 analysts
$84.00
30.22% Downside
 +94.0% ·
ZBIO
Zenas BioPharma, Inc.
 Feb 03, 2025 BUY Strong Buy
+52.5% avg upside
11 analysts
$19.00
33.17% Downside
 +281.4% ·
ORKA
Oruka Therapeutics
 Feb 03, 2025 BUY Strong Buy
+37.2% avg upside
16 analysts
$20.00
79.43% Downside
 +650.8% ·
VRDN
Viridian Therapeutics
 Jun 10, 2024 BUY Strong Buy
+42.6% avg upside
32 analysts
$29.00
17.63% Upside
 +29.0% ·
CRSP
Crispr Therapeutics AG
 Feb 14, 2024 HOLD Buy
+45.6% avg upside
41 analysts
 — -32.9% ·
STTK
Shattuck Labs
 Oct 25, 2023 BUY Strong Buy
+276.2% avg upside
16 analysts
$4.00
27.98% Downside
 +19.2% ·
AFMDQ
Affimed
 Aug 10, 2023 BUY Buy
+1359021112.1% avg upside
16 analysts
$60.00
5999999900.10% Upside
 · ·
🔒 25 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andy Chen — Frequently Asked Questions
How accurate are Andy Chen's stock ratings?
Based on the calls 13Foresight could measure, about 52% of Andy's ratings were profitable over a one-year hold, with an average return of +20.3% per rating, or +8.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Andy ranked on 13Foresight?
Andy Chen is currently ranked #1393 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andy cover?
Andy most recently has ratings on ROIV, INSM, KYMR, MDGL, VRTX, SYRE, NTLA, IONS, SRPT, CLDX, ABVX, VERA and 18 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.